Literature DB >> 1771090

Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder?

F G Zitman1, A C G Linssen, P M Edelbroek, G M J Van Kempen.   

Abstract

In a double-blind, crossover study, the effects of 75 mg amitriptyline alone during 5 weeks on pain intensity were compared with the effects of a combination of 75 mg amitriptyline and 3 mg flupentixol during 5 weeks in 34 patients with somatoform pain disorder. Both treatments resulted in a statistically significant reduction in pain. However, pain reduction in the combined treatment did not differ from that in the treatment with amitriptyline as a single drug. Neither tardive dyskinesias nor other serious side effects were observed. The results do not support the clinical practice of adding low-dose neuroleptics to low-dose antidepressants in the treatment of somatoform pain disorder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1771090     DOI: 10.1016/0304-3959(91)90007-K

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  5 in total

Review 1.  Antidepressants as analgesics: a review of randomized controlled trials.

Authors:  M E Lynch
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

2.  The management of "psychogenic" orofacial pain.

Authors:  S Hunter
Journal:  BMJ       Date:  1992-02-08

3.  [Psychopharmacological treatment in patients with somatoform disorders and functional body syndromes].

Authors:  H P Kapfhammer
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

Review 4.  Amitriptyline for fibromyalgia in adults.

Authors:  R Andrew Moore; Sheena Derry; Dominic Aldington; Peter Cole; Philip J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2019-05-28

Review 5.  Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states.

Authors:  H M Bryson; M I Wilde
Journal:  Drugs Aging       Date:  1996-06       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.